James Byrd
Department of Gastroenterology Hepatology and Nutrition, Division of Internal Medicine
Present Title & Affiliation
Primary Appointment
Associate Professor, Department of Gastroenterology - Research, Division of Internal Medicine, University of Texas MD Anderson Cancer Center, Houston, TX
Education & Training
Degree-Granting Education
| 1979 | Vanderbilt University, Nashville, NY, USA, PHD, Molecular Biology |
| 1973 | Massachusetts Institute of Technology, Cambridge, MA, USA, BS, Life Sciences |
Postgraduate Training
| 1979-1982 | Research Fellowship, Division of Labs and Research, NY State Dept of Health, Albany, NY |
Experience & Service
Academic Appointments
Staff Investigator, Department of Gastrointestinal Cancer Research Lab, Henry Ford Health Sciences Cent, Detroit, MI, 1996 - 2002
Associate Staff Investigator, Department of Gastrointestinal Cancer Research Lab, Henry Ford Health Sciences Center, Detroit, MI, 1993 - 1996
Asst Research Biochemist, University of California at San Francisco, San Francisco, CA, 1990 - 1993
Research Chemist, Department of Gastrointestinal Research Lab, VA Medical Center, San Francisco, CA, 1982 - 1990
Research Associate, Shriver Center for Mental Retardation, Waltham, MA, 1971 - 1973
Selected Publications
Peer-Reviewed Articles
- Mazurek N, Byrd JC, Sun Y, Hafley M, Ramirez K, Burks J, Bresalier RS. Cell-surface galectin-3 confers resistance to TRAIL by impeding trafficking of death receptors in metastatic colon adenocarcinoma cells. Cell Death Differ 19(3):523-33, 2012. e-Pub 2011. PMID: 21941373.
- Mazurek N, Byrd JC, Sun Y, Ueno S, Bresalier RS. A galectin-3 sequence polymorphism confers TRAIL sensitivity to human breast cancer cells. Cancer 117(19):4375-80, 2011. e-Pub 2011. PMID: 21446041.
Abstracts
- Ilmer M, Mazurek N, Hafley M, Vykoukal J, Alt E, Byrd JC, Bresalier RS. A TRAIL-resistant subset of colon cancer initiating stem cells characterized by surface galectin-3. Gastroenterology 144 Suppl 1:S-462, 2014.
- Ilmer M, Mazurek N, Byrd J, Alt E, Vykoukal J, Bresalier R.. Low surface Gal3 expression in breast cancer stem cells is associated with chemoresistance, tumorigenesis, and decreased overall patient survival. Proc Am Assoc Cancer Res, 2014.
- Mazurek N, Byrd JC, Ilmer M, Bresalier RS. Cell-surface expression of the anti-apoptotic beta-galactoside-binding protein galectin-3 is characteristic of the stem cell phenotype in colorectal cancer cells. Gastroenterology 142 Suppl 1:S-329, 2012.
Book Chapters
- Byrd JC, Mazurek N, Bresalier RS. Post-Translational Modification of Galectin-3 and Its Role in Biological Function. In: Galectins and Disease Implications for Targeted Therapeutics. American Chemical Society, Chapter 8, pp 137–151, 2012.